1. IB-tekst Copaxone via www.emea.europa.eu. Additionele informatie kan worden gevonden op www.cvz.nl, onderzoek, genees- en hulpmiddelen, cfh-toetsen
2. Bornstein MB, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-414.
3. Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45; 1268-1276.
4. Johnson KP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-708.
5. Johnson KP, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-266.
6. Comi G, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.
7. Khan OA, et al. A prospective, open-label treatment trial to compare the effect of IFN b -1a (Avonex), IFN b -1b (Betaferon), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8: 141-148.
8. Khan OA, et al. A prospective, open-label treatment trial to compare the effect of IFN b -1a (Avonex®), IFN b -1b (Betaferon®) and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7: 349-353.